Drug Trial Radar · NCT07777120
Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Mar 24, 2026
Primary completion
Mar 31, 2048
Study completion Mar 31, 2048
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Aug 20, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This non-interventional study will use information already reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) registry during routine clinical care. The study will assess the long-term safety and effectiveness of lisocabtagene maraleucel in participants with relapsed/refractory marginal zone lymphoma.
Conditions
- Marginal Zone Lymphoma
Interventions
lisocabtagene maraleucelBiological
As per United States prescribing information
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of selected adverse events after lisocabtagene maraleucel infusionTime frame: Up to 15 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center for International Blood and Marrow Transplant Research (CIBMTR)
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.